Loading...
  • disease
  • The fact that these patients were all homosexuals suggests an association between some aspect of a homosexual lifestyle or disease acquired through sexual contact and Pneumocystis pneumonia in this population. (cdc.gov)
  • prophylaxis
  • Which of the following is true regarding prophylaxis for Pneumocystis pneumonia? (valuemd.com)
  • A. This patient may be a candidate for Pneumocystis pneumonia prophylaxis, but he should be considered for prophylaxis only if his CD4 cell count is less than 200 cells/mm3. (valuemd.com)
  • B. The patient should be started on prophylaxis for Pneumocystis pneumonia, but given his history of pruritis and rash, trimethoprim-sulfamethoxazole would not be an option. (valuemd.com)
  • C. The patient should be started on Pneumocystis pneumonia prophylaxis using trimethoprim-sulfamethoxazole. (valuemd.com)
  • He should be admitted to the hospital and bronchoscopy performed to rule out active Pneumocystis pneumonia prior to receiving prophylaxis. (valuemd.com)
  • The correct answer is C. Trimethoprim-sulfamethoxazole is the preferred agent for Pneumocystis pneumonia prophylaxis. (valuemd.com)
  • A history of trimethoprim-sulfamethoxazole rash would not be an absolute contraindication to using trimethoprim-sulfamethoxazole for Pneumocystis prophylaxis, except in those persons who had a serious or life-threatening reaction, such as *******-Johnson syndrome. (valuemd.com)
  • Fever
  • His pneumonia responded to a course of intravenous TMP/.SMX, but, as of the latest reports, he continues to have a fever each day. (cdc.gov)
  • Monoclonal
  • NEW ORLEANS & ROCHESTER, N.Y.-(BUSINESS WIRE)-MiniVax, Inc. (New Orleans, LA) and the University of Rochester (Rochester, NY) announce that they have entered into an exclusive option agreement with agreed licensing terms to develop a monoclonal antibody for the treatment of Pneumocystis pneumonia (PCP). (rochester.edu)
  • inflammation
  • Our previous results show that treatment with glycosphingolipid synthesis inhibitor PDMP reduces the fungus lung burden as well as symptoms of inflammation in mice with Pneumocystis pneumonia (PCP). (jimmunol.org)
  • Animals were infected with live organisms, or challenged with either beta-glucan (the pro-inflammatory component of Pneumocystis cell wall) or LPS (inducer of lung inflammation unrelated to Pneumocystis ). (jimmunol.org)
  • In contrast, although LPS induces comparable intensity of inflammation as live Pneumocystis or glucan, PDMP does not suppress any inflammatory parameters measured in this group. (jimmunol.org)